Financial Data and Key Metrics Changes - Worldwide sales for Q1 2024 were $21.4 billion, an increase of 3.9% year-over-year, with U.S. growth at 7.8% and a decline of 0.3% outside the U.S. [8] - Net earnings for the quarter were $5.4 billion, with diluted earnings per share at $2.20, compared to a loss per share of $0.19 a year ago. Adjusted net earnings were $6.6 billion, with adjusted diluted earnings per share at $2.71, representing increases of 3.8% and 12.4% respectively compared to Q1 2023 [8][18]. Business Line Data and Key Metrics Changes - Innovative Medicine sales were $13.6 billion, up 2.5%, with U.S. growth of 8.4% and a decline of 4% outside the U.S. Excluding the COVID-19 vaccine, operational sales growth was 8.3% [9]. - MedTech sales reached $7.8 billion, increasing by 6.3%, with U.S. growth of 6.6% and 6.1% outside the U.S. [13]. Market Data and Key Metrics Changes - Sales growth in Europe, excluding the COVID-19 vaccine, was 6% [8]. - The pulmonary hypertension segment saw growth of 22.4%, driven by favorable patient mix and share gains for OPSUMIT and UPTRAVI [11]. Company Strategy and Development Direction - The company announced the acquisition of Shockwave Medical to enhance its cardiovascular portfolio, aligning with its strategy to become a best-in-class MedTech company [21]. - The completion of the Ambrx acquisition was highlighted as a move to strengthen the oncology portfolio [21]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving long-term growth goals with an operational sales compounded annual growth rate of 5% to 7% from 2025 to 2030 [41]. - The company anticipates continued growth in Innovative Medicine, particularly in the second half of the year, despite expected competition from biosimilars [34]. Other Important Information - The company invested $3.5 billion in R&D, representing 16.6% of sales, and announced a 4.2% increase in dividends, marking the 62nd consecutive year of dividend increases [31][32]. - The effective tax rate for the quarter was 16.9%, significantly lower than the previous year's 61.8% due to a tax benefit related to the talc settlement proposal [18]. Q&A Session Summary Question: Insights on CARVYKTI and TECVAYLI sales performance - Management noted that CARVYKTI saw over 100% growth year-over-year, with strong demand and expanded manufacturing capacity. TECVAYLI is performing well with strong uptake in major markets [37][44][45]. Question: MedTech growth and one-time items impact - MedTech growth was reported at 6.3%, with double-digit growth in electrophysiology. One-time items included fewer selling days and revenue recognition changes impacting orthopedics [48][50]. Question: Future M&A strategy - The company emphasized a disciplined M&A strategy focused on long-term growth, with flexibility to consider various transaction types, including smaller and earlier-stage assets [54][56]. Question: Vision Care business performance - Management acknowledged recent performance issues in the Vision Care segment due to distributor inventory contraction but expressed confidence in the underlying health of the business and expected high single-digit growth for 2024 [58][59]. Question: Pulmonary Hypertension business growth - The segment experienced strong growth driven by OPSUMIT and UPTRAVI, with the introduction of OPSYNVI expected to enhance the portfolio further [63]. Question: SPRAVATO growth context - SPRAVATO showed over 70% growth, with strong uptake in treatment-resistant depression, and the company remains optimistic about its future performance [84]. Question: Drug price negotiations under IRA - Management expressed concerns about the IRA's impact on innovation but remains focused on patient access and ongoing discussions regarding pricing [86].

Johnson & Johnson’s (JNJ) first-quarter 2024 earnings came in at $2.71 per share, which beat the Zacks Consensus Estimate of $2.64. Earnings rose 12.4% from the year-ago period.Adjusted earnings exclude intangible amortization and some other special items. Including these items, J&J reported first-quarter earnings of $2.20 per share against a loss of 19 cents in the year-ago quarter.Sales of this drug and medical devices giant came in at $21.38 billion, missing the Zacks Consensus Estimate of $21.40 billion ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

For the quarter ended March 2024, Johnson & Johnson (JNJ) reported revenue of $21.38 billion, down 13.6% over the same period last year. EPS came in at $2.71, compared to $2.68 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $21.4 billion, representing a surprise of -0.09%. The company delivered an EPS surprise of +2.65%, with the consensus EPS estimate being $2.64.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall S ...

Key TakeawaysJohnson & Johnson shares slipped following the release of a first-quarter earnings report that included sales figures below estimates, but better-than-expected income.The company also increased its dividend, marking 62 straight years it has done so.Johnson & Johnson narrowed its full-year guidance, projecting increases to sales and adjusted earnings per share (EPS) of about 5% and 7%, respectively. Johnson & Johnson (JNJ) posted a mixed first-quarter earnings Tuesday, and raised its dividend wh ...

Key PointsJohnson & Johnson's mixed quarter revealed core strength and a widening margin. Guidance was raised with the mid-point for earnings above consensus. Analysts support this market and see it advancing at least 10%. 5 stocks we like better than Johnson & JohnsonShares of Johnson & Johnson NYSE: JNJ are as cheap as they will get. The stock is down in premarket trading following the Q1 release, but there is a bottom in play and reality to face. Trading near $145, JNJ stock is valued at less than 14X th ...

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.71 per share, beating the Zacks Consensus Estimate of $2.64 per share. This compares to earnings of $2.68 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 2.65%. A quarter ago, it was expected that this world's biggest maker of health care products would post earnings of $2.27 per share when it actually produced earnings of $2.29, delivering a surprise of 0.88%. Ov ...

st April 16, 2024 Cautionary note on Forward-looking statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate o ...

An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019.Johnson & Johnson on Tuesday reported first-quarter adjusted earnings that topped Wall Street's expectations as sales in its medical devices business surged.Meanwhile, the company's total revenue for the period was largely in line with estimates.J&J's medtech division provides devices for surgeries, orthopedics and vision. The company is benefiting from a rebound in demand for nonurgent surgeries among ol ...

Investors are always looking for stocks that are poised to beat at earnings season and Johnson & Johnson (JNJ) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Johnson & Johnson is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty ...